Ocugen director granted 170,100 stock options

Ocugen, Inc. director Chandrasekhar Satishchandran received a grant of stock options covering 170,100 shares of common stock.

Rhea-AI Filing Summary

Ocugen, Inc. director Chandrasekhar Satishchandran received a grant of stock options covering 170,100 shares of common stock. The options have an exercise price of $1.22 per share and expire on June 11, 2036.

The award vests upon the earlier of June 11, 2027 or Ocugen’s next annual meeting of stockholders, subject to his continued service through the vesting date. After this grant, his reported derivative holdings in this award total 170,100 options.

Insider Trade Summary

Grant/Award: 170,100 shares

Grant/Award 1 txn

Insider Chandrasekhar Satishchandran

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (Right to Buy)	170,100	$0.00	$0.00

Holdings After Transaction: Stock Option (Right to Buy) — 170,100 contracts (Direct)

Footnotes (1)

1. F1. The option vests upon the earlier of (a) June 11, 2027 or (b) Ocugen, Inc.'s next annual meeting of stockholders, subject to the Reporting Person's continued service through the applicable vesting date.

Key Figures

Option grant size: 170,100 options Exercise price: $1.22 per share Underlying shares: 170,100 shares +3 more

6 metrics

Option grant size 170,100 options Stock Option (Right to Buy) granted on June 11, 2026

Exercise price $1.22 per share Conversion or exercise price of the stock option grant

Underlying shares 170,100 shares Common stock underlying the granted options

Expiration date June 11, 2036 Option expiration for this grant

Vesting date trigger June 11, 2027 or next annual meeting Earlier of two dates, subject to continued service

Post-grant derivative holdings 170,100 options Total options from this award following the transaction

Key Terms

Stock Option (Right to Buy), exercise price, vesting, annual meeting of stockholders

4 terms

Stock Option (Right to Buy) financial

"security_title: "Stock Option (Right to Buy)""

exercise price financial

"conversion_or_exercise_price: "1.2200" per share"

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

vesting financial

"The option vests upon the earlier of (a) June 11, 2027 or (b) Ocugen, Inc.'s next annual meeting"

Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.

annual meeting of stockholders financial

"or (b) Ocugen, Inc.'s next annual meeting of stockholders"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Ocugen (OCGN) director Chandrasekhar Satishchandran report on this Form 4?

He reported receiving a grant of stock options for 170,100 shares of Ocugen common stock. These options are a compensation award and give him the right to buy shares at a fixed exercise price in the future.

How many Ocugen (OCGN) stock options were granted and at what exercise price?

The grant covers 170,100 stock options with an exercise price of $1.22 per share. This means he can purchase Ocugen common stock at $1.22 per share once the options vest and are exercisable, subject to the plan terms.

When do Chandrasekhar Satishchandran’s Ocugen (OCGN) options vest?

The options vest on the earlier of June 11, 2027 or Ocugen’s next annual meeting of stockholders. Vesting is conditioned on his continued service with the company through the applicable vesting date, according to the footnote disclosure.

What is the expiration date of the Ocugen (OCGN) stock options granted?

These stock options expire on June 11, 2036 if not exercised earlier. After that date, the right to purchase Ocugen common stock under this grant lapses, so any unexercised options would no longer be usable.

Is this Ocugen (OCGN) Form 4 a market purchase or sale of shares?

No, this Form 4 reflects a compensation-related stock option grant, not an open-market trade. The reported transaction is a grant or award acquisition, giving a right to buy shares later at $1.22 per share.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 06/15/2026 - 04:33 PM EDT Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Chandrasekhar Satishchandran

(Last) (First) (Middle)

C/O OCUGEN, INC.

11 GREAT VALLEY PARKWAY

(Street)

MALVERN PENNSYLVANIA 19355

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Ocugen, Inc. [ OCGN ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/11/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$1.22	06/11/2026		A		170,100		(1)	06/11/2036	Common Stock	170,100	$0	170,100	D

Explanation of Responses:

1. The option vests upon the earlier of (a) June 11, 2027 or (b) Ocugen, Inc.'s next annual meeting of stockholders, subject to the Reporting Person's continued service through the applicable vesting date.

	/s/ Shankar Musunuri, attorney-in-fact	06/15/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)